Shams, Naveed
AAVantgarde Bio srl, Milan, Italy.
3 papers on CoChatORCID 0009-0001-8484-6032
Most cited papers
- Verified
Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration: PIER Study Year 1
Regillo, C. D., Brown, D. M., Abraham, P., Yue, H., Ianchulev, T., Schneider, S., & Shams, N. (2008) · American Journal of Ophthalmology
Retinal Diseases and TreatmentsRetinal and Macular Surgery
Cited by 858
- Verified
Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration
FERRARA, N., DAMICO, L., SHAMS, N., LOWMAN, H., & KIM, R. (2006) · Retina
Retinal Diseases and TreatmentsAngiogenesis and VEGF in Cancer
Cited by 849
- Verified
Retinal gene therapy for Stargardt disease with dual AAV intein vectors is both safe and effective in large animal models
Ferla, R., Pugni, E., Lupo, M., Tiberi, P., Fioretto, F., Perota, A., Duchi, R., Lagutina, I., Gesualdo, C., Rossi, S., et al. (2025) · Science Advances
Retinal Development and DisordersVirus-based gene therapy research
Cited by 19
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free